<DOC>
	<DOCNO>NCT00002616</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Peripheral stem cell transplantation combine biological therapy may effective treatment breast cancer . PURPOSE : Phase I trial study effectiveness interleukin-2 filgrastim stimulate cell production treat patient stage IIIB , stage IV , metastatic , recurrent breast cancer undergo peripheral stem cell transplantation .</brief_summary>
	<brief_title>Biological Therapy Plus Peripheral Stem Cell Transplantation Treating Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose continuous infusion interleukin-2 ( IL-2 ) combine standard dose filgrastim ( G-CSF ) stimulate peripheral blood stem cell ( PBSC ) harvest patient advance breast cancer . II . Assess PBSC engraftment follow high dose cyclophosphamide , thiotepa , carboplatin ( STAMP V regimen ) support G-CSF IL-2/G-CSF hematopoietic support patient underwent pretransplant PBSC stimulation . III . Characterize toxic effect combine IL-2 G-CSF . IV . Compare immune function change follow IL-2/G-CSF G-CSF alone assess expression CD56/CD56-bright , CD3 , CD25 ; natural killer cell lymphokine activate killer cell activity ; T-cell response ( TT , HER2/neu ) ; serum level interleukin-6 , tumor necrosis factor , G-CSF . V. Compare effect expression circulate hematopoietic progenitor cell ( CD34+ , CFU-GM , BFU-GM ) range IL-2 dos combine G-CSF achieve G-CSF alone . VI . Compare time neutrophil platelet recovery , requirement red blood cell platelet transfusion , time hospital discharge patient receive IL-2/G-CSF-primed vs. G-CSF-primed PBSC follow STAMP V chemotherapy . VII . Compare feasibility , toxicity , hematologic immunologic effect post-PBSC infusion IL-2/G-CSF vs. G-CSF alone . VIII . Assess response rate , duration response , disease free interval patient advance breast cancer treat STAMP V PBSC rescue . IX . Assess presence cytokeratin marker minimum residual disease measure blood marrow polymerase chain reaction follow treatment . OUTLINE : Patients assign 1 4 treatment group peripheral blood stem cell stimulation ( prim ) therapy stem cell transplantation . All patient receive prim therapy filgrastim ( G-CSF ) alone interleukin-2 ( IL-2 ) , stem cell harvest . Patients adequate harvest receive high dose cyclophosphamide , thiotepa , carboplatin ( STAMP V ) follow stem cell rescue subsequent G-CSF without IL-2 , follow : Arm I receive G-CSF alone prim follow stem cell transplant . Arm II receive G-CSF prim alone G-CSF/IL-2 follow transplant . Arm III receive various dos G-CSF/IL-2 prim G-CSF follow transplant . Arm IV receive various level G-CSF/IL-2 prim fix dos G-CSF/IL-2 follow transplant . Cohorts 3-6 patient treat treatment arm escalating dose IL-2 . The maximum tolerate dose define dose less 2 6 patient experience dose limit toxicity . Patients follow disease progression survival . PROJECTED ACCRUAL : Approximately 36 patient accrue study 18-24 month ; maximum 12 patient receive G-CSF prim alone ( 6 without 6 post-PBSC IL-2 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced breast cancer eligible ( patient refuse participation ) high priority phase III SWOG study Local stage IIIB/IV disease , i.e . : Inflammatory Fixed chest wall Fixed axillary lymph node Recurrent disease Metastatic disease Disease stable responsive standard dose systemic chemotherapy Measurable evaluable disease require except : Unevaluable stage IV disease ( beyond drain lymph node ) eligible follow surgical resection , radiotherapy , chemotherapy Less 30 % bone marrow involvement aspiration biopsy No active brain metastasis CT MRI require unless asymptomatic history brain metastases No large symptomatic pleural effusion PATIENT CHARACTERISTICS : Age : Under 65 Performance status : SWOG 0 1 Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL ALT/AST great 2 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : Left ventricular ejection fraction least 45 % MUGA No angina No history myocardial infarction Exercise stress test without definite ischemia require : History suggestive coronary disease Diabetes mellitus Hypertension Age 50 Pulmonary : FEV1 great 60 % predict great 2.0 liter DLCO great 60 % predict Other : No prior hemorrhagic cystitis No active systemic infection No active CNS disease ( e.g. , seizure ) HIV negative No second malignancy within 2 year except : Localized nonmelanomatous skin cancer Carcinoma situ cervix Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since chemotherapy recover No 2 different prior chemotherapy regimens metastatic disease No prior mitomycin nitrosourea Lifetime cumulative doxorubicin dose le 350 mg per square meter Endocrine therapy : Not specify Radiotherapy : At least 2 week since radiotherapy recover Surgery : At least 3 week since major surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>